Nicodemus Christopher F
AIT Strategies, POB 429 Sunset Lane, Franconia, NH 03580, USA.
Immunotherapy. 2015;7(8):923-39. doi: 10.2217/imt.15.57. Epub 2015 Aug 28.
Monoclonal antibodies remain a primary product option for novel cancer treatment. The properties of an antibody are a function of the antigen specificity and constant region incorporated. The rapid advance in molecular understanding of cancer biology and the host-tumor interaction has defined a new range of targets for antibody development. The clinical success of the checkpoint inhibitors has validated immune modulation and mobilization as a therapeutic approach. Solid cancers are distinguished from hematologic malignancies because the solid tumor stroma contains significant tumor promoting and immune dampening elements less prominent in hematologic cancer. This review highlights how engineered monoclonal antibody products are emerging as potential cornerstones of new more personalized cancer treatment paradigms that target both tumor and the stromal environment.
单克隆抗体仍然是新型癌症治疗的主要产品选择。抗体的特性是抗原特异性和所包含恒定区的函数。对癌症生物学和宿主-肿瘤相互作用的分子理解的迅速进展，为抗体开发确定了一系列新的靶点。检查点抑制剂的临床成功验证了免疫调节和动员作为一种治疗方法的有效性。实体癌与血液系统恶性肿瘤不同，因为实体瘤基质含有显著的肿瘤促进和免疫抑制成分，而这些成分在血液系统癌症中不那么突出。本综述强调了工程单克隆抗体产品如何正在成为新的、更个性化的癌症治疗模式的潜在基石，这些模式同时针对肿瘤和基质环境。
